Shares of Neurometrix Inc (NASDAQ:NURO) saw strong trading volume on Friday . 1,181,800 shares traded hands during trading, an increase of 719% from the previous session’s volume of 144,280 shares.The stock last traded at $0.47 and had previously closed at $0.38.

A number of equities research analysts have recently weighed in on the company. Zacks Investment Research lowered Neurometrix from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. ValuEngine raised Neurometrix from a “hold” rating to a “buy” rating in a research note on Tuesday, July 2nd.

The business has a 50 day moving average price of $0.36 and a two-hundred day moving average price of $0.66.

Neurometrix (NASDAQ:NURO) last released its earnings results on Thursday, July 18th. The medical device company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.02. Neurometrix had a negative return on equity of 17.31% and a negative net margin of 23.52%. The company had revenue of $2.36 million during the quarter, compared to analyst estimates of $3.28 million. On average, equities analysts anticipate that Neurometrix Inc will post -0.35 earnings per share for the current year.

An institutional investor recently raised its position in Neurometrix stock. Acadian Asset Management LLC increased its stake in Neurometrix Inc (NASDAQ:NURO) by 386.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 104,605 shares of the medical device company’s stock after acquiring an additional 83,102 shares during the period. Acadian Asset Management LLC owned about 1.07% of Neurometrix worth $43,000 as of its most recent SEC filing. Institutional investors own 16.91% of the company’s stock.

Neurometrix Company Profile (NASDAQ:NURO)

NeuroMetrix, Inc, a healthcare company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes.

Featured Story: What is the float in trading stocks?

Receive News & Ratings for Neurometrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurometrix and related companies with MarketBeat.com's FREE daily email newsletter.